Next Article in Journal / Special Issue
How Nanotechnology and Biomedical Engineering Are Supporting the Identification of Predictive Biomarkers in Neuro-Oncology
Previous Article in Journal
Dental Application of Natural Products
Previous Article in Special Issue
Current and Future Applications of Biomedical Engineering for Proteomic Profiling: Predictive Biomarkers in Neuro-Traumatology
Article Menu

Export Article

Open AccessPerspective
Medicines 2018, 5(1), 22; https://doi.org/10.3390/medicines5010022

Understanding the Pathological Basis of Neurological Diseases Through Diagnostic Platforms Based on Innovations in Biomedical Engineering: New Concepts and Theranostics Perspectives

1
School of Medicine, University of Cagliari, 09124 Cagliari, Italy
2
John Radcliffe Hospital, Oxford University, Oxford OX3 9DU, UK
3
Fondazione IRCCS Istituto Neurologico “Carlo Besta”, 20133 Milano, Italy
4
Department of Neurosurgery, Toronto Western Hospital, University of Toronto, Toronto, ON M5T 2S8, Canada
*
Author to whom correspondence should be addressed.
Received: 1 January 2018 / Revised: 14 February 2018 / Accepted: 20 February 2018 / Published: 25 February 2018
(This article belongs to the Special Issue New Innovations in Biomedical Engineering)
View Full-Text   |   Download PDF [1072 KB, uploaded 25 February 2018]   |  

Abstract

The pace of advancement of genomics and proteomics together with the recent understanding of the molecular basis behind rare diseases could lead in the near future to significant advances in the diagnosing and treating of many pathological conditions. Innovative diagnostic platforms based on biomedical engineering (microdialysis and proteomics, biochip analysis, non-invasive impedance spectroscopy, etc.) are introduced at a rapid speed in clinical practice: this article primarily aims to highlight how such platforms will advance our understanding of the pathological basis of neurological diseases. An overview of the clinical challenges and regulatory hurdles facing the introduction of such platforms in clinical practice, as well as their potential impact on patient management, will complement the discussion on foreseeable theranostic perspectives. Indeed, the techniques outlined in this article are revolutionizing how we (1) identify biomarkers that better define the diagnostic criteria of any given disease, (2) develop research models, and (3) exploit the externalities coming from innovative pharmacological protocols (i.e., those based on monoclonal antibodies, nanodrugs, etc.) meant to tackle the molecular cascade so far identified. View Full-Text
Keywords: biomarkers; proteomics; nanotechnology; precision medicine; neurosurgery biomarkers; proteomics; nanotechnology; precision medicine; neurosurgery
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Ganau, L.; Prisco, L.; Ligarotti, G.K.; Ambu, R.; Ganau, M. Understanding the Pathological Basis of Neurological Diseases Through Diagnostic Platforms Based on Innovations in Biomedical Engineering: New Concepts and Theranostics Perspectives. Medicines 2018, 5, 22.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Medicines EISSN 2305-6320 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top